Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2011

View Archived Issues

CH-4938056 targets microtubule-associated protein 4 to confer antitumor activity

New bivalent immunotoxin shows promise to treat solid tumors

MK-3475 enters phase I trial in patients with solid tumors

Antibodies against adalimumab are linked to diminished long-term treatment response

Egis Pharma creates new agents for CNS disorders

New lysophospholipid receptor antagonists reported by Amira Pharma

FDA committee recommends approval of telaprevir for genotype 1 chronic hepatitis C

ISTA reports topline phase II data on bepotastine besilate in seasonal allergic rhinitis

R-507 and R-545 reduce acute cellular rejection in vivo

InterMune claims new inhibitors of HCV serine protease NS3

Nabi Biopharma achieves final milestone in sale of PentaStaph vaccine to GSK

First selective ganglioside biosynthesis inhibitors identified at Zacharon Pharma

Takeda identifies new inhibitors of mitogen-activated protein kinase kinase kinase 5

Vandetanib launched in U.S. for advanced medullary thyroid cancer

New alpha2C-adrenoceptor modulators identified

FDA approves fixed-dose combination of ibuprofen and famotidine

Phase IIb trial compares AR-12286 to latanoprost in ocular hypertension

KemPharm and MonoSol Rx join to develop KP-106 oral film for ADHD

Dainippon Sumitomo Pharma and Maruho collaborate to develop new topical analgesic

HemaQuest Pharma enrolls first patient in phase II HQK-1001 trial

FDA approves Menactra meningococcal conjugate vaccine for infants

FDA approves Abbott's AndroGel 1.62% for treatment of men with hypogonadism

FDA approves Fusilev in combination with 5-FU for colorectal cancer

Last infant vaccinated with MVA-85A in phase IIb trial

Otonomy reports encouraging phase Ib data on OTO-104 in Meniere's disease

FDA grants orphan drug status to CytRx's INNO-206 in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...